Strata Oncology
- Company typePrivate
- Founded2016
- HeadquartersAnn Arbor, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
Strata Oncology firmographics
Firmographics- Name
- Strata Oncology
- Legal name
- Strata Oncology, Inc.
- Website
- https://strataoncology.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Strata Oncology industry classification
Industry- Product category
- Precision Oncology Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)
Keywords
Where Strata Oncology is headquartered
LocationHeadquarters
- HQ city
- Ann Arbor
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Strata Oncology business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Molecular Profiling Testing Services: Strata Oncology generates revenue through clinical molecular profiling tests, including Strata Select, which provides treatment selection guidance for advanced cancer patients. Medicare coverage has been obtained for eligible beneficiaries. Revenue is derived from reimbursement from Medicare, commercial insurers, and potentially direct contracts with health systems.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Strata Select test at $6,500 list charge, with Medicare coverage for qualifying patients |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Strata Oncology product offering
Product offeringCore offering
Strata Oncology is a precision oncology company that operates a CLIA-certified laboratory delivering Strata Select, a pan-solid tumor molecular profiling test combining DNA sequencing with quantitative RNA gene expression on a single small tumor tissue sample. The test incorporates proprietary multivariate biomarker algorithms—Immunotherapy Response Score (IRS) for predicting anti-PD-1/PD-L1 checkpoint inhibitor benefit and ADC Treatment Response Score (ADC TRS) for predicting antibody-drug conjugate response—to guide treatment selection for patients with advanced cancer.
Product overview
Strata Oncology offers a precision oncology platform centered on advanced algorithmic biomarkers. The core offering is Strata Select, a pan-solid tumor molecular profiling test launched in April 2023 that provides treatment selection guidance for immunotherapy and other treatments. Strata Select incorporates the Immunotherapy Response Score (IRS) for predicting anti-PD-1/PD-L1 benefit and also delivers ADC Treatment Response Score (ADC TRS) results. These proprietary biomarkers were developed using data from the Strata Trial observational clinical trial. The Strata PATH trial extends the platform to prospective interventional studies of FDA-approved therapies in biomarker-guided populations.
Differentiator
Problem solved
Functional benefit
Brands
- Strata Select: A first-of-its-kind pan-solid tumor molecular profiling solution for patients with advanced cancer that provides treatment selection guidance for immunotherapy and beyond.
- Immunotherapy Response Score (IRS)
- ADC Treatment Response Score (ADC TRS)
- Strata Trial
Products and services
- Strata Select A pan-solid tumor molecular profiling test for patients with advanced cancer that provides treatment selection guidance for immunotherapy and beyond. Combines DNA sequencing with quantitative RNA gene expression on a single small tumor tissue sample, and includes the proprietary Immunotherapy Response Score (IRS) and ADC Treatment Response Score (ADC TRS) biomarker algorithms. Ordered by oncologists and cancer treatment centers from Strata Oncology's CLIA-certified laboratory; Medicare coverage available for qualifying beneficiaries at a $6,500 list charge.
- Immunotherapy Response Score (IRS) A pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit. Combines tissue-based tumor mutation burden (TMB) with quantitative expression of PD-L1, PD-1, ADAM12, and TOP2A to identify which patients are likely to benefit from immunotherapy versus combination therapy. Delivered as part of Strata Select.
- ADC Treatment Response Score (ADC TRS) A predictive biomarker for benefit from a variety of approved and investigational antibody-drug conjugates (ADCs). Based on a proprietary calculation method combining ADC target expression, proliferation, and adhesion as measured by RNAseq. Validated across multiple tumor types and ADC targets. Delivered as part of Strata Select and available to biopharma partners for ADC clinical trial patient selection.
Quantifiable outcome
- IRS-H patients treated with pembrolizumab had median TTNT of 20.3 months vs 4.5 months on prior therapy (log-rank p<0.0001), while IRS-L patients had no benefit (3.3 vs 5.2 months, p=0.75)
- +3 more outcomes
Companies that use Strata Oncology
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Strata Oncology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Strata Oncology partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Kaiser Permanente Northern CaliforniacoreKaiser Permanente Northern California conducted independent evaluations of Strata Oncology's Immunotherapy Response Score (IRS) using real-world patient data. KPNC oncologists, blinded to TRS status, determined best response to therapy from chart review. 211 KPNC patients from 24 solid tumor types were included in the pembrolizumab evaluation. 117 KPNC patients with bladder or breast cancer were evaluated for ADC TRS. This partnership generated peer-reviewed publications validating the biomarkers.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Strata Oncology competitors and assessment
Company assessmentDirect peers
- Foundation Medicine: Foundation Medicine (owned by Roche) offers FoundationOne CDx, a leading pan-solid tumor comprehensive genomic profiling test. Direct competitor to Strata Select in oncology molecular profiling and biomarker-driven clinical trial patient selection for pharma partners.
- Personalis: Personalis offers NeXT Personal, a tumor-informed liquid biopsy and molecular profiling assay. Comparable in pan-solid tumor molecular profiling with both clinical and biopharma/biodefense customers, with overlapping DNA+RNA multi-omics approach.
- Guardant Health: Guardant Health provides liquid biopsy and molecular profiling for oncology, including Guardant360 for tumor profiling. Comparable in precision oncology diagnostics and biopharma CDx development, though Strata is tissue-based rather than blood-based.
- Caris Life Sciences: Caris offers MI Profile (DNA/RNA molecular profiling) and Caris Assure (liquid biopsy) for oncology treatment selection. Closely comparable to Strata in molecular profiling services and biopharma companion-diagnostic partnerships.
- Tempus AI: Tempus provides AI-enabled precision medicine including its xT and xR oncology assays covering DNA/RNA sequencing for solid tumors. Directly comparable to Strata in pan-solid tumor profiling for both oncologist ordering and biopharma partnerships.
Broad incumbents
- NeoGenomics: NeoGenomics is a larger oncology-focused clinical laboratory services company offering comprehensive molecular profiling, FISH, IHC, and cytogenetics tests. Overlaps with Strata in oncology testing services but is a much broader portfolio player.
- Exact Sciences: Exact Sciences is a publicly-traded cancer diagnostics leader (Cologuard, Oncotype DX). While primarily known for colorectal screening and breast cancer recurrence testing, it competes in precision oncology decision support and biomarker-driven testing.
- Resolution Bioscience (Agilent): Resolution Bioscience, acquired by Agilent, offers liquid biopsy NGS for oncology. Overlaps with Strata in oncology molecular profiling and biopharma CDx development but operates within a much larger life sciences tools parent.
- Natera: Natera offers Signatera (tumor-informed MRD) and other oncology molecular tests. Comparable in molecular diagnostics and biopharma partnerships, with broader presence in reproductive testing as well.
Emerging players
- Adaptive Biotechnologies: Adaptive Biotechnologies offers clonoSEQ (MRD) and immune profiling assays. Comparable in molecular diagnostics for oncology treatment monitoring with biopharma partnership model, though focused on immuno-sequencing rather than tumor profiling.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Strata Oncology social profiles
Digital presenceStrata Oncology compliance and trust
Trust signalCompliance1 record
Strata Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Strata Oncology leadership team
Management profileNumber of profiles
Profiles14 records
Strata Oncology funding detail
Funding detailFunding overview
Funding rounds3 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Strata Oncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Strata Oncology
What does Strata Oncology do?
Strata Oncology is a precision oncology company that operates a CLIA-certified laboratory delivering Strata Select, a pan-solid tumor molecular profiling test combining DNA sequencing with quantitative RNA gene expression on a single small tumor tissue sample. The test incorporates proprietary multivariate biomarker algorithms—Immunotherapy Response Score (IRS) for predicting anti-PD-1/PD-L1 checkpoint inhibitor benefit and ADC Treatment Response Score (ADC TRS) for predicting antibody-drug conjugate response—to guide treatment selection for patients with advanced cancer.
Is Strata Oncology a public or private company?
Strata Oncology is a private company. It is classified as venture growth investor backed and is currently operating.
When was Strata Oncology founded?
Strata Oncology was founded in 2016. It employs 51 to 100 people.
Where is Strata Oncology based?
Strata Oncology is headquartered in Ann Arbor, United States, in the North America region.
How does Strata Oncology make money?
One revenue line is on record: molecular Profiling Testing Services.
Who are Strata Oncology's main competitors?
Direct peers on record are Foundation Medicine, Personalis, Guardant Health, Caris Life Sciences and Tempus AI. Broad incumbents are NeoGenomics, Exact Sciences, Resolution Bioscience (Agilent) and Natera. Adaptive Biotechnologies is listed as an emerging player.
Does Strata Oncology have an API?
No public API is recorded for Strata Oncology.
What industry is Strata Oncology in?
Strata Oncology's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLACAGAH, Oncology Pathways & Precision Medicine Decision Support. Its NAICS code is 621511 and its SIC code is 8071.